Tokuyama Yoshiko, Iwamura Masatsugu, Fujita Tetsuo, Sugita Atsushi, Maeyama Ryota, Bessho Hideharu, Ishikawa Wataru, Tabata Ken-ichi, Yoshida Kazunari, Baba Shiro
The Department of Urology, Kitasato University School of Medicine, Japan.
Hinyokika Kiyo. 2011 Oct;57(10):555-8.
We present a case of myocardial metastasis from renal cell carcinoma (RCC) during the treatment with sorafenib. A 63-year-old male, who had undergone right radical nephrectomy, received interferon-alpha (IFN), interleukin (IL-2) and 5-flurouracil (5-FU) for the treatment of lung and pleural metastases. However, since this metastasis showed progressive disease, we administered sorafenib. Nine months after the introduction of sorafenib, he complained of dyspnea. Chest computed tomography and cardiac ultrasonography revealed a low density mass at the cardiac muscle of the left cardiac ventricle, suggesting myocardial metastasis of RCC. Molecular targeted therapy achieved a longer survival in advanced RCC patients in comparison with the immunotherapy using cytokines. Therefore, in metastasis evaluation, some organs which have been regarded as rare sites should be carefully evaluated.
我们报告一例在索拉非尼治疗期间发生肾细胞癌(RCC)心肌转移的病例。一名63岁男性,曾接受右肾根治性切除术,接受过α干扰素(IFN)、白细胞介素(IL-2)和5-氟尿嘧啶(5-FU)治疗肺和胸膜转移。然而,由于这种转移显示疾病进展,我们给予了索拉非尼治疗。在开始使用索拉非尼九个月后,他出现呼吸困难。胸部计算机断层扫描和心脏超声检查显示左心室心肌有低密度肿块,提示RCC心肌转移。与使用细胞因子的免疫疗法相比,分子靶向治疗使晚期RCC患者的生存期更长。因此,在转移评估中,一些被视为罕见转移部位的器官应仔细评估。